Carmelo Dueñas-Castell

Prof. Carmelo Dueñas-Castell

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2010 in Critical Care
Verified
Journal Article
Open access
PDF file
JSJorge I. F. Salluh
Jorge I. F. Salluh
MSMarcio Soares
Marcio Soares
JTJosé M Teles
José M Teles
DCDaniel Ceraso
Daniel Ceraso
NRNestor Raimondi
Nestor Raimondi
MRMarcelo G Rocha
Marcelo G Rocha
Introduction: Delirium is a frequent source of morbidity in intensive care units (ICUs). Most data on its epidemiology is from single-center studies. Our aim was to conduct a multicenter study to evaluate the epidemiology of delirium in the ICU. Methods: A 1-day point-prevalence study was undertaken in 104 ICUs from 11 countries in South and North America and Spain. Results: In total, 975 patients were screened, and 497 fulfilled inclusion criteria and were enrolled (median age, 62 years; 52.5% men; 16.7% and 19.9% for ICU and hospital mortality); 64% were admitted to the ICU because of medical causes, and sepsis was the main diagnosis (n = 76; 15.3%). In total, 265 patients were sedated with the Richmond agitation and sedation scale (RASS) deeper than -3, and only 232 (46.6%) patients could be evaluated with the confusion-assessment method for the ICU. The prevalence of delirium was 32.3%. Compared with patients without delirium, those with the diagnosis of delirium had a greater severity of illness at admission, demonstrated by higher sequential organ-failure assessment (SOFA (P = 0.004)) and simplified acute physiology score 3 (SAPS3) scores (P < 0.0001). Delirium was associated with increased ICU (20% versus 5.7%; P = 0.002) and hospital mortality (24 versus 8.3%; P = 0.0017), and longer ICU (P < 0.0001) and hospital length of stay (LOS) (22 (11 to 40) versus 7 (4 to 18) days; P < 0.0001). Previous use of midazolam (P = 0.009) was more frequent in patients with delirium. On multivariate analysis, delirium was independently associated with increased ICU mortality (OR = 3.14 (1.26 to 7.86); CI, 95%) and hospital mortality (OR = 2.5 (1.1 to 5.7); CI, 95%). Conclusions: In this 1-day international study, delirium was frequent and associated with increased mortality and ICU LOS. The main modifiable risk factors associated with the diagnosis of delirium were the use of invasive devices and sedatives (midazolam).

1 January 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
APAngel Paternina-Caicedo
Angel Paternina-Caicedo
Jezid MirandaJezid Miranda
Jezid Miranda
GBGhada Bourjeily
Ghada Bourjeily
ALAndrew Levinson
Andrew Levinson
CDCarmelo Dueñas-Castell
Carmelo Dueñas-Castell
JRJosé A. Rojas-Suarez
José A. Rojas-Suarez

1 December 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
USUgarte Ubiergo Sebastián
Ugarte Ubiergo Sebastián
ARArenas Villamizar Angel Ricardo
Arenas Villamizar Angel Ricardo
BABruno C. Alvarez
Bruno C. Alvarez
ACAngela Mayerly Cubides-Munevar
Angela Mayerly Cubides-Munevar
ALAngélica F. Luna
Angélica F. Luna
JMJohn C. Marshall
John C. Marshall

1 July 2022 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
APAngel Paternina-Caicedo
Angel Paternina-Caicedo
MJMark Jit
Mark Jit
NANelson Alvis-Guzmán
Nelson Alvis-Guzmán
JFJuan Carlos Fernández
Juan Carlos Fernández
JHJosé Hernández
José Hernández
FHFernando De La Hoz-Restrepo
Fernando De La Hoz-Restrepo
In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deaths in a cohort of 796,072 insured subjects older than 40 years in northern Colombia, a setting with a high SARS-CoV-2 transmission. We identified individuals vaccinated between March 1st of 2021 and August 15th of 2021. We included symptomatic cases, hospitalizations, critical care admissions, and deaths in patients with confirmed COVID-19 as main outcomes. We calculated VE for each outcome from the hazard ratio in Cox proportionally hazards regressions (adjusted by age, sex, place of residence, diabetes, human immunodeficiency virus, cancer, hypertension, tuberculosis, neurological diseases, and chronic renal disease), with 95% confidence intervals (CI). A total of 719,735 insured participants of 40 and more years were followed. We found 21,545 laboratory-confirmed symptomatic COVID-19 among unvaccinated population, along with 2874 hospitalizations, 1061 critical care admissions, and 1329 deaths, for a rate of 207.2 per million person-days, 27.1 per million person-days, 10.0 per million person-days, and 12.5 per million person-days, respectively. We found CoronaVac was not effective for any outcome in subjects above 80 years old; but for people 40-79 years of age, we found two doses of CoronaVac reduced hospitalization (33.1%; 95% CI, 14.5–47.7), critical care admission (47.2%; 95% CI, 18.5–65.8), and death (55.7%; 95% CI, 32.5–70.0). We found BNT162b2 was effective for all outcomes in the entire population of subjects above 40 years of age, significantly declining for subjects ≥80 years. Two doses of either CoronaVac in population between 40 and 79 years of age, or BNT162b2 among vaccinated above 40 years old significantly reduced deaths of confirmed COVID-19 in a cohort of individuals from Colombia. Vaccine effectiveness for CoronaVac and BNT162b2 declined with increasing age. UK National Institute for Health Research, the European Union's Horizon 2020 research and innovation programme, and the Bill & Melinda Gates Foundation.

1 January 2016 in Revista Brasileira de Terapia Intensiva
Verified
Journal Article
Open access
GOGuillermo Ortiz
Guillermo Ortiz
CDCarmelo Dueñas-Castell
Carmelo Dueñas-Castell

Verified
Journal Article
Open access
PDF file
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Jose Alfredo Correa GuerreroJose Alfredo Correa Guerrero
Jose Alfredo Correa Guerrero
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
MBMaría Bonilla-Llanos
María Bonilla-Llanos
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
CDCarmelo Dueñas-Castell
Carmelo Dueñas-Castell
Lung-protective ventilation and other experimental conditions raise arterial carbon dioxide tension (PaCO2) and alter pH. Short-term benefits are reported in non-infectious settings, whereas infection and/or prolonged exposure are typically harmful. This scoping review systematically maps immune-mediated effects of hypercapnia on innate immunity and alveolar epithelial repair. Scoping review per Levac et al. and PRISMA Extension for Scoping Reviews (Open Science Framework protocol: 10.17605/OSF.IO/WV85T; post hoc). We searched original preclinical studies (in vivo/in vitro) in PubMed, Web of Science, ScienceDirect, Cochrane Reviews, and SciELO (2008–2023). PaCO2 (mmHg) was prioritized; %Fraction of inspired Carbon Dioxide (%FiCO2) was recorded when PaCO2 was unavailable; pH was classified as buffered/unbuffered. Data were organized by context, PaCO2, and exposure duration; synthesis used heat maps (0–120 h) and a narrative description for >120 h. Mechanistic axes extracted the following: NF-κB (canonical/non-canonical), Bcl-2/Bcl-xL–Beclin-1/autophagy, AMPK/PKA/CaMKKβ/ERK1/2 and ENaC/Na,K-ATPase trafficking, Wnt/β-catenin in AT2 cells, and miR-183/IDH2/ATP. Thirty-five studies met the inclusion criteria. In non-infectious models, a “protective window” emerged, with moderate PaCO2 and brief exposure (65–95 mmHg; ≤4–6 h), featuring NF-κB attenuation and preserved epithelial ion transport. In infectious models and/or with prolonged exposure or higher PaCO2, harmful signals predominated: reduced phagocytosis/autophagy (Bcl-2/Bcl-xL–Beclin-1 axis), AMPK/PKA/ERK1/2-mediated internalization of ENaC/Na,K-ATPase, depressed β-catenin signaling in AT2 cells, impaired alveolar fluid clearance, and increased bacterial burden. Chronic exposures (>120 h) reinforced injury. Hypercapnia is a context-, dose-, time-, and pH-dependent double-edged modulator. The safe window is narrow; standardized, parallel reporting of PaCO2 and pH—with explicit comparisons of buffered vs. unbuffered hypercapnia—is essential to guide clinical translation.